Suzhou Guangxin Biotechnology

Guangxin Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on the DNA damage response (DDR) pathway and the regulation of deubiquitinating enzymes (DUBs) to treat various cancers. Its lead candidate, GX-001, is a highly selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1) that has entered Phase 1 clinical trials in both China and the United States. Guangxin Biotech aims to address unmet medical needs in patients with homologous recombination deficient (HRD) tumors, including those with BRCA mutations, through precision medicine approaches.